Vigil Neuroscience Inc (VIGL) - News Archive

In a groundbreaking development for those battling Alzheimer s disease, Vigil Neuroscience has unveiled promising preclinical and clinical data at the prestigious AD/PD 2025 International Conference regarding their inno...

Vigil Neuroscience Advances in Neurodegenerative Treatments: FDA Lift on VG-3927 Clinical Hold and Strategic Plans for Iluzanebart In a significant stride towards combating neurodegenerative diseases, Vigil Neuroscience...

Understanding the Landscape of ALSP and Genetic ContributionsOn July 18, 2024, Vigil Neuroscience, Inc. (Nasdaq: VIGL), a promising player in the field of biotechnology, released a significant update pertaining to the g...

Vigil Neuroscience, a pioneering biotechnology company, has recently unveiled encouraging interim data from its ongoing Phase 1 clinical trial evaluating VG-3927 in healthy volunteers. The results underscore the safety,...

In a recent update, Vigil Neuroscience, a pioneering biotechnology company, shared its progress in pursuing an accelerated approval pathway for their therapeutic candidate, Iluzanebart. Specifically designed for the tre...

In a recent press release, Vigil Neuroscience Inc. announced a significant strategic investment from Sanofi, amounting to $40 million. The investment was made at an as-converted price of $7.44 per share of common stock....

Vigil Neuroscience, a leading biopharmaceutical company, recently announced its financial results for the first quarter of 2024 while also providing a business update. A significant development shared in the update was...

The American Academy of Neurology s 2024 Annual Meeting has recently showcased the breakthrough discoveries from two significant studies: ILLUMINATE and IGNITE, casting a spotlight on the complex disease that is Adult-o...

Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) is a rare neurodegenerative disorder that presents with variable symptoms, often resembling multiple sclerosis (MS). Genetic testing plays...

As we close the chapter on 2023 and look forward to what lies ahead in the field of neuroscience, Vigil Neuroscience shines a light on its remarkable achievements and highlights exciting milestones slated for 2024. With...